Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 20;27(6):459-465.
doi: 10.3779/j.issn.1009-3419.2024.106.12.

[Research Progress on Predictive Biomarkers of Immunotherapy Efficacy in Non-small Cell Lung Cancer]

[Article in Chinese]
Tiansheng Sun  1 , Zhang Chen  1 , Kunchen Wei  1 , Hao Tang  1
Affiliations
Review

[Research Progress on Predictive Biomarkers of Immunotherapy Efficacy in Non-small Cell Lung Cancer]

[Article in Chinese]
Tiansheng Sun et al. Zhongguo Fei Ai Za Zhi. .

Abstract
in English, Chinese

Lung cancer is one of the most common malignant tumors in the world, of which non-small cell lung cancer (NSCLC) is the majority. The emergence of immune checkpoint inhibitors (ICIs) has greatly changed the treatment strategy of NSCLC and improved the prognosis of patients. However, in reality, only a small number of patients can achieve long-term benefit. Therefore, the identification of reliable predictive biomarkers is essential for the selection of treatment modalities. With the development of molecular biology and genome sequencing technology in recent years, as well as the in-depth understanding of tumor and its host immune microenvironment, research on biomarkers has emerged in an endless stream. This review focuses on the predictive biomarkers of immunotherapy efficacy in NSCLC, in order to provide some guidance for precision immunotherapy. .

【中文题目：非小细胞肺癌免疫治疗疗效的 预测生物标志物研究进展】 【中文摘要：肺癌是世界上最常见的恶性肿瘤之一，其中非小细胞肺癌（non-small cell lung cancer, NSCLC）占大多数。免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）的出现极大地改变了NSCLC的治疗策略，并改善了患者预后，然而现实中只有少部分患者能够获得长期受益。因此，确定可靠的预测生物标志物对选择治疗方式至关重要。随着近年来分子生物学、基因组测序技术的发展以及对肿瘤及其宿主免疫微环境的认识不断深入，生物标志物的研究层出不穷。本文围绕NSCLC免疫治疗疗效的预测生物标志物进行综述，以期为精准免疫治疗提供指导。 】 【中文关键词：肺肿瘤；免疫治疗；肿瘤突变负荷；生物标志物；预测】.

Keywords: Biomarker; Immunotherapy; Lung neoplasms; Prognostication; Tumor mutational burden.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare that they have no competing interests.

References

    1. Leiter A, Veluswamy RR, Wisnivesky JP. . The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol, 2023, 20(9): 624-639. doi: 10.1038/s41571-023-00798-3 - DOI - PubMed
    1. Nicholson AG, Tsao MS, Beasley MB, et al. . . The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol, 2022, 17(3): 362-387. doi: 10.1016/j.jtho.2021.11.003 - DOI - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. . . Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer. N Engl J Med, 2016, 375(19): 1823-1833. doi: 10.1056/NEJMoa1606774 - DOI - PubMed
    1. Mok TSK, Wu YL, Kudaba I, et al. . . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 2019, 393(10183): 1819-1830. doi: 10.1016/s0140-6736(18)32409-7 - DOI - PubMed
    1. Aguilar EJ, Ricciuti B, Gainor JF, et al. . . Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol, 2019, 30(10): 1653-1659. doi: 10.1093/annonc/mdz288 - DOI - PubMed

MeSH terms

Substances